PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
65.60%
Revenue growth above 1.5x ACB.TO's 20.24%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
109.55%
Gross profit growth above 1.5x ACB.TO's 63.72%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
77.73%
EBIT growth above 1.5x ACB.TO's 42.49%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
77.73%
Operating income growth above 1.5x ACB.TO's 3.21%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
115.00%
Net income growth above 1.5x ACB.TO's 33.40%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
115.13%
EPS growth above 1.5x ACB.TO's 35.63%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
114.87%
Diluted EPS growth above 1.5x ACB.TO's 35.63%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.41%
Share reduction more than 1.5x ACB.TO's 3.52%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
1.04%
Diluted share reduction more than 1.5x ACB.TO's 3.52%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
14.93%
Similar OCF growth to ACB.TO's 14.40%. Walter Schloss would assume comparable operations or industry factors.
21.35%
Positive FCF growth while ACB.TO is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1088.27%
3Y revenue/share CAGR under 50% of ACB.TO's 3873.40%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
-5491.93%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-3771.73%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-1815.90%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
1243.82%
Positive 10Y CAGR while ACB.TO is negative. John Neff might see a substantial advantage in bottom-line trajectory.
413.21%
Positive 5Y CAGR while ACB.TO is negative. John Neff might view this as a strong mid-term relative advantage.
272.91%
Positive short-term CAGR while ACB.TO is negative. John Neff would see a clear advantage in near-term profit trajectory.
5974.97%
10Y equity/share CAGR above 1.5x ACB.TO's 3748.55%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
13212.67%
5Y equity/share CAGR is in line with ACB.TO's 12091.55%. Walter Schloss would see parallel mid-term profitability and retention policies.
1278.80%
Below 50% of ACB.TO's 5010.60%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
27.87%
AR growth well above ACB.TO's 34.60%. Michael Burry fears inflated revenue or higher default risk in the near future.
3.14%
Inventory shrinking or stable vs. ACB.TO's 40.73%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
15.58%
Asset growth 1.25-1.5x ACB.TO's 13.82%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
-2.05%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
513.53%
Debt growth far above ACB.TO's 83.88%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
14.17%
R&D dropping or stable vs. ACB.TO's 94.15%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-22.82%
We cut SG&A while ACB.TO invests at 24.30%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.